CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
48.45
-1.64 (-3.27%)
Mar 18, 2026, 2:22 PM EDT - Market open
CRISPR Therapeutics AG Revenue
In the year 2025, CRISPR Therapeutics AG had annual revenue of $3.51M, down -90.59%. CRISPR Therapeutics AG had revenue of $864.00K in the quarter ending December 31, 2025, a decrease of -97.58%.
Revenue (ttm)
$3.51M
Revenue Growth
-90.59%
P/S Ratio
1,318.91
Revenue / Employee
$8,931
Employees
393
Market Cap
4.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.51M | -33.80M | -90.59% |
| Dec 31, 2024 | 37.31M | -333.89M | -89.95% |
| Dec 31, 2023 | 371.21M | 370.01M | 30,885.48% |
| Dec 31, 2022 | 1.20M | -913.77M | -99.87% |
| Dec 31, 2021 | 914.96M | 914.24M | 127,154.94% |
| Dec 31, 2020 | 719.00K | -288.87M | -99.75% |
| Dec 31, 2019 | 289.59M | 286.47M | 9,169.85% |
| Dec 31, 2018 | 3.12M | -37.87M | -92.38% |
| Dec 31, 2017 | 41.00M | 35.83M | 693.90% |
| Dec 31, 2016 | 5.16M | 4.92M | 1,990.69% |
| Dec 31, 2015 | 247.00K | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caris Life Sciences | 812.03M |
| Amicus Therapeutics | 634.21M |
| TG Therapeutics | 616.29M |
| Ligand Pharmaceuticals | 268.09M |
| Xenon Pharmaceuticals | 7.50M |
CRSP News
- 7 days ago - CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering - GlobeNewsWire
- 8 days ago - CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering - GlobeNewsWire
- 27 days ago - Crispr Therapeutics: Very High Risk But Even Higher Potential Reward - Seeking Alpha
- 27 days ago - CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript - Seeking Alpha
- 4 weeks ago - CRISPR Therapeutics Q4: The Elite Time To Buy Is In 2027 - Seeking Alpha
- 4 weeks ago - CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens - Benzinga
- 4 weeks ago - CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Crispr Therapeutics: Patience And Opportunity Through Volatility - Seeking Alpha